Skip to main content

Table 1 Comparisons of multiple factors between RP-ILD and non-RP-ILD groups

From: The lungs were on fire: a pilot study of 18F-FDG PET/CT in idiopathic-inflammatory-myopathy-related interstitial lung disease

Factors

RP-ILD (21)

Non-RP-ILD (40)

P value

P-adjusted

Age(y)

54.86 ± 11.72

57.70 ± 11.06

0.354

0.824

Sex (male/female)

8/13

17/23

0.740

1.000

Course of disease(m)

2.00 (1.00, 2.75)

2.25 (1.00, 5.00)

0.253

0.748

Duration of diagnosis delay(m)

1.50 (0.50, 2.00)

1.00 (1.00, 3.00)

0.274

0.756

Clinical manifestations or complications

 

 Pulmonary bacterial infection

7 (33.3%)

4 (10.0%)

0.036

0.347

 Pulmonary fungal infection

5 (23.8%)

4 (10.0%)

0.253

0.748

 Tuberculosis infection

0 (0.0%)

0 (0.0%)

NA

NA

 EBV infection

6 (28.6%)

5 (12.5%)

0.164

0.605

 CMV infection

2 (9.5%)

0 (0.0%)

0.115

0.559

 Carcinoma

1 (4.8%)

6 (15.0%)

0.405

0.824

 Gastrointestinal haemorrhage

4 (19.0%)

1 (2.5%)

0.044

0.347

 UIP pattern

3 (14.3%)

4 (10.0%)

0.683

0.962

 Pneumomediastinum

1 (4.8%)

1 (2.5%)

1.000

1.000

Laboratory finding

 Ferritin (ng/ml)

612.50 (302.05, 2110.25)

664.05 (314.40, 2061.23)

0.495

0.863

 ESR (mm/h)

16.00 (6.50, 32.00)

17.50 (9.50, 42.00)

0.466

0.857

 CRP (mg/L)

5.40 (3.10, 19.80)

6.35 (3.00, 36.73)

0.660

0.962

 ALT(U/L)

37.00 (22.50, 99.50)

91.50 (33.75, 212.50)

0.051

0.347

 AST(U/L)

45.00 (33.00, 97.00)

54.50 (34.00, 235.50)

0.224

0.725

 LDH(U/L)

329.00 (275.50, 478.50)

323.00 (247.75, 461.50)

0.897

1.000

 CK(U/L)

84.00 (50.50, 255.00)

86.00 (44.25, 415.25)

0.838

1.000

Disease activity

 

 MYOACT score

13.00 (9.00, 15.50)

9.00 (7.00, 10.75)

0.006

0.102

Lung function testing

 

 FVC% (%)

65.33 ± 20.08

71.86 ± 15.61

0.165

0.605

 FEV1% (%)

64.85 ± 19.40

74.42 ± 18.25

0.062

0.383

 FEV1/FVC

0.81 (0.75, 0.85)

0.81 (0.77,0.85)

0.849

1.000

 TLC(L)

3.43 ± 1.01

3.98 ± 1.02

0.049

0.347

 DLCO% (%)

50.29 ± 15.58

66.92 ± 16.67

< 0.001

0.014

18F-FDG PET/CT scan findings

 Time gap after RS onset*(d)

20.00 (12.50, 25.00)

16.50 (13.00, 24.75)

0.767

1.000

 Bilateral lung SUVmean

0.60 ± 0.15

0.45 ± 0.14

< 0.001

0.014

 Abnormal mediastinal lymph node

14 (66.7%)

10 (25.0%)

0.002

0.045

 Abnormal hilar lymph node

11 (52.4%)

9 (22.5%)

0.018

0.204

 Liver SUVmean

1.83 ± 0.34

1.73 ± 0.47

0.412

0.824

 Spleen SUVmean

2.02 ± 0.50

1.82 ± 0.46

0.126

0.571

 Bone marrow SUVmean

1.72 ± 0.50

1.62 ± 0.44

0.402

0.824

 Cardiac SUVmean

1.38 (1.00, 2.03)

1.60 (1.12, 2.39)

0.379

0.824

 Oesophagus SUVmean

1.51 (1.19, 1.83)

1.34 (1.07, 1.74)

0.213

0.724

 Stomach SUVmean

0.69 (0.49, 1.00)

0.71 (0.57, 0.83)

0.927

1.000

 Small intestine SUVmean

1.05 ± 0.33

1.03 ± 0.32

0.878

1.000

 Colon and rectum SUVmean

1.07 (0.80, 1.32)

1.02 (0.83, 1.20)

0.693

0.962

 Bilateral cerebellum SUVmean

5.17 ± 1.26

5.24 ± 1.61

0.863

1.000

 Bilateral trapezius SUVmean

0.82 (0.70, 0.96)

0.79 (0.68, 1.00)

0.585

0.944

 Bilateral deltoid SUVmean

0.71 (0.58, 1.27)

0.78 (0.61, 1.09)

0.590

0.944

 Bilateral biceps SUVmean

0.75 (0.67, 1.01)

0.77 (0.60, 1.10)

0.879

1.000

 Bilateral iliopsoas SUVmean

1.10 ± 0.36

1.12 ± 0.36

0.850

1.000

 Bilateral gluteus maximus SUVmean

0.85 ± 0.27

0.79 ± 0.32

0.462

0.857

 Bilateral gluteus medius SUVmean

0.92 ± 0.29

0.98 ± 0.29

0.473

0.857

 Bilateral quadriceps SUVmean

0.78 (0.62, 0.96)

0.82 (0.69, 1.05)

0.370

0.824

Myositis-specific antibodies and myositis-associated antibodies

 

 Anti-MDA5

13 (61.9%)

12 (30.0%)

0.016

0.204

 Anti-PL-7

4 (19.0%)

2 (5.0%)

0.169

0.605

 Anti-PL-12

1 (4.8%)

1 (2.5%)

1.000

1.000

 Anti-EJ

0 (0.0%)

1 (2.5%)

1.000

1.000

 Anti-OJ

0 (0.0%)

1 (2.5%)

1.000

1.000

 Anti-Jo-1

2 (9.5%)

3 (7.5%)

1.000

1.000

 Anti-TIF1γ

1 (4.8%)

3 (7.5%)

1.000

1.000

 Anti-Mi-2α

0 (0.0%)

2 (5.0%)

0.541

0.920

 Anti-Mi-2β

0 (0.0%)

4 (10.0%)

0.289

0.756

 Anti-SAE1

0 (0.0%)

5 (12.5%)

0.154

0.605

 Anti-NXP2

1 (4.8%)

6 (15.0%)

0.405

0.824

 Anti-SRP

1 (4.8%)

2 (5.0%)

1.000

1.000

 Anti-Ku

1 (4.8%)

1 (2.5%)

1.000

1.000

 Anti-PM-Scl75

1 (4.8%)

2 (5.0%)

1.000

1.000

 Anti-PM-Scl100

0 (0.0%)

0 (0.0%)

NA

NA

 Anti-Ro-52

14 (66.7%)

17 (42.5%)

0.073

0.414

Therapies

 

 Steroid monotherapy

6 (28.6%)

14 (35.0%)

0.611

0.944

 Steroid + DMARDs

7 (33.3%)

19 (47.5%)

0.288

0.756

 Steroid+IVIG

2 (9.5%)

2 (5.0%)

0.602

0.944

 Steroid+DMARDs+IVIG

3 (14.3%)

4 (10.0%)

0.683

0.962

 Steroid + JAK inhibitor

3 (14.3%)

1 (2.5%)

0.113

0.559

IIM subtypes

 

 DM

13 (61.9%)

27 (67.5%)

0.662

0.962

 PM

2 (9.5%)

7 (17.5%)

0.479

0.857

 ADM

6 (28.6%)

6 (15.0%)

0.309

0.778

  1. RP-ILD, rapidly progressive interstitial lung disease; P-adjusted, adjusted P value after false discovery rate correction; y, years; m, months; NA, not available; EBV, Epstein-Barr virus; CMV, cytomegalovirus; UIP pattern, usual interstitial pneumonia pattern; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein; ALT, alanine transaminase; AST, aspartate transaminase; LDH, lactate dehydrogenase; CK, creatine kinase; MYOACT, Myositis Disease Activity Assessment Visual Analogue Scales; FVC%, percent-predicted forced vital capacity; FEV1%, percent-predicted forced expiratory volume in 1 s; FEV1/FVC, ratio of FEV1 over FVC; TLC, total lung capacity; DLCO%, percent-predicted diffusing capacity of the lung for carbon monoxide; RS, respiratory symptoms; d, days; FDG, fluorodeoxyglucose; SUVmean, mean standard uptake value; DMARDs, disease-modifying anti-rheumatic drugs; IVIG, intravenous immunoglobulin; JAK, Janus kinase; IIM, idiopathic inflammatory myopathy; DM, dermatomyositis; PM, polymyositis; ADM, amyopathic dermatomyositis
  2. *Time gap after RS onset referred to the time gap between onset of respiratory symptoms (evident feelings of chest distress and shortness of breath) and PET/CT scan
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us